Helmedix debuts with funding from MRCF

Helmedix Pty. Ltd. (Sydney, Australia) debuted on Thursday with A$1.3 million ($1.3 million) in seed funding from Australia's Medical Research Commercialization Fund (MRCF) to develop peptides to prevent and treat autoimmune diseases. The newco is based on IP from the ithree institute at the University of Technology Sydney, which covers immune-modulating peptides derived from helminth worms. The seed funding will be used for lead optimization and preclinical development of the peptides over the next two years. Helmedix said it will seek further investment or industry partnerships to advance the peptides through clinical development. ...